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Abstract To clarify the clinical features of pulmonary Mycobacterium avium^intracellulare complex (MAC) infection,
we retrospectively evaluated clinicalmanifestations, laboratory data, chest andmaxillary sinus computed tomographic
scans andinduced sputumfindingsin 26 withMACinfectionin comparisonwith104 patientswithtuberculosis (TB) infec-
tion.We found that carbohydrate antigen 19-9 (CA19-9) and immunoglobulin A (IgA) in the serum and percentage of
neutrophils in the sputumwere significantly higher, and sinusitis was significantly more frequent in patients with MAC
comparedwithpatientswithTB.MACinfectionmightbemore stronglyassociatedwithimpairedupper andlower airway
defensemechanismin comparisonwithTB.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1496, available online at http://www.sciencedirect.com
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Mycobacterium infections are divided into Mycobacter-
ium tuberculosis (TB) and nontuberculous mycobacter-
iosis (NTM).Mycobacterium avium^intracellulare complex
(MAC) is the most common among NTM capable of
causing disease in humans.The human immunode¢ciency
virus (HIV) epidemic has changed the epidemiology of
NTM infections.On the other hand, in HIV-negative pa-
tients, NTM infection usually occurs in patients with da-
maged lungs, including those with chronic obstructive
lung disease (COPD), pulmonary tuberculosis, bronch-
iectasis, and pneumoconiosis (1,2) as well as in patients
without predisposing lung disease(3,4).
The pathology of MAC infection has not been fully
solved compared with tuberculosis. There are some dif-
ferences in the radiographic ¢ndings ofNTMlungdisease
comparedwith those causedbyTB.Recent studies invol-
ving high-resolution computed tomography (HRCT) of
the chest have shown that up to 90% of patients with
middle and lower lung ¢eld noncavitary disease with
MAC infection have associated multifocal bronchiecta-Received14 July 2002, accepted in revised form 4Nov 2002
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nodules in associated areas of the lung (3,5,6).The signs
and symptoms of pulmonary MAC infection are variable
and nonspeci¢c.There is no di¡erence in the symptoms
between NTM and TB lung diseases. Evaluation is often
di⁄cult due to the symptoms of co-existing lung dis-
eases.Most patients with NTM infection are middle and
elder women (3,4). Pulmonary MAC infection mainly af-
fects the small airways (7) andneutrophil andCD4+lym-
phocyte counts in bronchoalveolar lavage are
signi¢cantly increased (8). Serum carbohydrate antigen
19-9 (CA19-9) re£ects the activity of MAC infection,
and chronic neutrophil-related in£ammation associated
with a decrease in CD4+ lymphocytes in bronchioles
and/or peripheral small airways is probably related to
the deterioration of this disorder (9). Thus, the clinical
features of pulmonary MAC are gradually becoming
clear. However, there have been very few studies that
compare the clinical features of MAC infection with
those of TB.
The low-dose long-term administration of clarithro-
mycin is e¡ective for intractable chronic sinusitis (10,11).
Tomoda et al. reported that mucociliary transport by
aerosol inhalation cine-scintigraphy was slower both in
main bronchus and in the trachea in patients with MAC
than in healthy controls (12). Although abnormalities of
the upper and lower respiratory tracts are considered
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proof in this regard. In the present study, we retrospec-
tively analyzed the clinical features, laboratory data,
maxillary sinus CT and induced sputum ¢ndings of pa-





fection and104 patients (32 women) with pulmonaryTB
infection, who visited Kanazawa Wakamastu Hospital
between April 1996 and March 2000 for the treatment,
were retrospectively studied. None of them had been
previously treated forMACorTBbeforevisitingourhos-
pital. Pulmonary MAC infectionwas diagnosed based on
the American Thoracic Society diagnostic criteria (13).
Diagnosis of pulmonary TB infection was made when
sputum cultures were positive forM. tuberculosis. All pa-
tients had chest radiographic and/or CT scan ¢ndings
suggestive of MAC infection or TB infection. MAC was
cultured in sputum on at least two separate occasions
and/or in samples obtained from the radiographically af-
fectedregions using a sterilized ¢beroptic bronchoscope
when patients had no sputum and/or negative-sputum
culture.The patients were free from other distinct lung
diseases, as judgedbymedical history andprevious chest
radiographic and/or CT ¢ndings.The patients had nega-
tive serologic ¢ndings for human immunode¢ciency virus
(HIV) type1and type 2 and they did not receive any im-
munosuppressive drugs.
Clinical data
Clinical data were collected on each patient, including
sex, age, height, body weight, body-mass index (BMI),
and routine laboratory tests; white blood cell counts
(WBC), erythrocyte sedimentation rate (ESR), blood
biochemistry, C-reactive protein (CRP), adenosine dea-
minase (ADA), carbohydrate antigen19-9 (CA19-9), lym-
phocyte subsets (CD4+, CD8+), and immunoglobulin A
and E were evaluated on admission.
Induced Sputum Study
On admission, sputum induction was performed by
trained respiratory technicians. After brushing and rin-
sing the teeth and oral cavity, patients were asked to in-
hale an aerosol of hypertonic (3%) saline generatedby an
ultrasonic nebulizer (OMRON NE-U12, Tokyo, Japan).
The ¢rst three expectorationswere collectedin a sterile
specimen cup.The specimenswere transported immedi-
ately to the microbiology laboratory for processing and
examination. Furthermore, we also obtained inducedsputum fromhealthy volunteers (n=20).Geckleret al. re-
ported that comparing the cultures of sputum speci-
ments with those of paired transtracheal aspirates the
agreement between sputa with o25 buccal squamous
epithelial cells per 100 ¢eld and transtracheal aspira-
tion was good (14). We de¢ned that the sputum with
o25 buccal squamous epithelial cells was adequate.
Bacteriology
Induced sputum samples and/or samples obtained by
bronchoscopy were stained with Ziehl^Neelsen stain
and cultured formycobacteria using 3%Ogawa eggmed-
ium.Cultures were quanti¢ed from zero to 4+ using the
published standards (15). Mycobacteria were identi¢ed
and di¡erentiatedbygrowth characteristics and conven-
tional biochemical tests. The materials were also cul-
tured for other bacteria and fungi by the routine
methods (15).
Paranasal sinuses ¢ndings
Paranasal sinuses CT scans were performed on admis-
sion and evaluated by a radiologist. The existence of
chronic sinusitis was diagnosed by an otolaryngologist in
our hospital.Chronic sinusitiswas diagnosed if the criter-
ia for the clinical de¢nitions of chronic sinusitis proposed
by Melen et al. were ful¢lled (16).The criteria are as fol-
lows: (1) Symptoms, i.e. facial pain, nasal congestion or
abnormal secretion, remain or reappear during a period
of at least 3 months. (2) Sinus radiography and/or sino-
scopy reveal persistent local or generalized mucosal
swelling with or without secretion. But in this study, si-
noscopy was notperfomed except a fewof patientswith
MAC because of the risk of infection.
Statistical analysis
Values are expressed as the mean7 standard error
of the mean (SEM) in the tables. For statistical
evaluation of di¡erences between the two
groups, we used the Mann^Whitney U test for
nonparametric data. For comparison between
the groups, we used Fisher’s Exact Probability
test. A P-value ofo0.05 was considered statis-
tically signi¢cant.
RESULT
All data in the tables are those obtained, when pulmon-
ary MAC infection or TB infection was diagnosed. The
clinical characteristics of the MAC and TB groups are
shown inTable1.The female rate of the MAC group was
signi¢cantly higher than that of theTB group (P=0.0036).
TABLE 1. Clinical Background of patientswithMycobacterium Avium^Intracellulare (MAC) and those tuberculosis (TB).
MAC (n=26) TB (n=104)
Total Men Women Total Men Women
(n=26) (n=10) (n=16) (n=104) (n=72) (n=32)
Age (years) 66.272.3 65.873.7 66.473.0 61.571.9 61.372.1 62.474.0
Older than 70 (%) 38.5 40 37.5 44.2 43.1 48.5
Bodyweight (cm) 153.571.7* 160.672.4 148.871.4 160.471.0 164.170.9 151.371.6
Bodyweight (kg) 44.671.6* 48.272.7 42.471.9
49.971.0 52.671.1
43.571.9
BMI 19.170.6 18.670.7 19.570.9 19.470.3 19.570.4 19.270.7
Cigarette smoker (%) 38.5w 70 25 60.6 87.5 36.4
Alcohol drinker % 34.6w 80 6.3z 58.7 72.2 30.3
*Po0.01comparedwithTB (total). wPo0.05 comparedwithTB (total). zPo0.05 comparedwithTB (women).
TABLE 2. Paranasal sinuses CTand Laboratorydata inMycobacterium Avium-Intracellulare (MAC) and those tuberculosis (TB).
MAC(n=26) TB(n=104) P-Value
Sinusitis positive % 47.1% 21.1% 0.0288
Sputumbacterial culture positive % 34.6% 26.5% 0.4096
WBCcells/ml 64087391 68837242 0.3651
Lymphocytes countcells/ml 13127108 1259767 0.7120
%CD4+% 46.172.4 49.571.3 0.9260
ADAIU/1 15.171.1 20.572.2 0.3395
CRPmg/dl 2.670.7 3.970.4 0.0359
ESRmm/hr 41.976.4 47.073.3 0.4630
TPg/dl 6.770.1 6.570.1 0.1095
Alb g/dl 3.670.1 3.370.1 0.0421
Ch-E IU/l 307.7721.6 258.0715.9 0.0185
CA19-9 U/ml 72.3735.8 24.373.8 0.0131
IgAmg/dl 444.4749.1 353.8718.2 0.0398
IgE IU/ml 245.2760.8 686.1781.1 0.1916
WBC: white blood cell,ADA: adenosine deaminase,CRP:C-reactive protein,ESR: erythrocyte sedimentationrate,TP: total
protein,Alb: albumin, ch-E: cholinesterase,CA19-9: carbohydrate antigen19-9,IgA: immunoglobulin A,IgE: immunoglobulin E
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groupwas signi¢cantly higher than in the MAC group.
The laboratorydata and theresultof paranasal sinuses
CTscans are shown inTable 2.Thepercentage of patients
having chronic sinusitis was signi¢cantly higher in the
MACgroup than in theTB group (Po0.03). Although ser-
um CRP and ESR in the MAC group were lower com-
pared with the TB group, the serum CA19-9 and IgA
levels in the MAC group were signi¢cantly higher than
in theTB group. Serum albumin and cholinesterase were
also signi¢cantly higher in the MAC group than in theTB
group. The result of other bacterial cultures, e.g. S. aur-
eus, Klebsiella sp., Ps. aeruginosa and so on did not di¡er
betweenTB group and MAC group inTable 2.
The induced sputum data from the MAC group, TB
group, and Control group are shown in the Fig. 1. Ade-
quate induced sputumwas obtained from eight patients
of the MAC group, 35 patients of theTB group, and 20healthy volunteers.The percentage of neutrophils in the
MAC group was signi¢cantly higher than that of theTB
group and healthy volunteers, whereas the percentage
of lymphocytes in theTB group was signi¢cantly higher
than that of the MAC group and healthy volunteers.
DISCUSSION
In the present study, we investigated the characteristics
of patientswithMAC infection in comparisonwith those
of patients withTB.One of the main results of the pre-
sent study was that the MAC group had chronic sinusitis
more frequently compared withTB. Moreover, the per-
centage of neutrophils in induced sputum in the MAC
group was signi¢cantly higher than that of theTB group
and healthy volunteers. This suggests the existence of
the in£ammation in respiratory tract, which releases
FIG 1. Percentages of di¡erential cells in induced sputum frompatients with MAC infection (n=8), patients withTB (n=32) infection
andhealthycontrols (n=20).Neu.: neutrophil.Lym.: lymphocyte.Ma.: macrophage.Eo.: eosinophil.
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cult for the cilia to transport, accumulates in the air-
ways, thus giving ample time for large amounts of
activated elastase to be released from neutrophils.Then,
by damaging the ciliated epithelium, the elastase re-
leased further impedes the transport of the sputum by
the cilia and allows further proliferation of the bacteria.
Because tuberculosis is splash infection, the functional
abnormalities of the upper respiratory tract are danger-
ous factors. But MAC had more abnormalities of the
upper respiratory tract compared with TB. We specu-
lated that abnormalities of the upper respiratory tract
in MAC patients might impede the transport of sputum
by the cilia and allow the attachment andproliferation of
MAC. This indicates that the pathogenesis of the MAC
infection may be similar to those of sinobronchial syn-
drome (SBS) (17) and di¡use panbronchiolitis (DPB)
(18,19). SBS and DPB are common chronic airway disor-
ders in Japan and a¡ectmainly women; the disorders are
characterized by chronic neutrophilic in£ammation of
the airways and sinobronchial mucociliary dysfunction.
Moreover, the results of this study also showed that ser-
um IgA and CA19-9 levels of the MAC groupwere signif-
icantly higher than those of theTB group. Secretory IgAis the predominant Ig isotype in airway secretion and
plays a key role in mucosal immunity. It is generated lo-
cally and selectively transported across the bronchial
mucosa into the respiratory secretion (20,21). Serum
CA 19-9, a tumor-associated carbohydrate antigen, is
known to be a useful marker for gastrointestinal malig-
nancies, particularly pancreas adenocarcinoma (22) The
elevated serum CA19-9 levels are seen in patients with
lung cancer (23). However, serum CA 19-9 is also
elevated in patients with nonmalignant lung diseases
such as idiopathic pulmonary ¢brosis (IPF), di¡use pan-
bronchiolitis (DPB), cystic ¢brosis, andpulmonary tuber-
culosis (24^26). The high serum CA19-9 is due to
hypersecretion of mucus glycoprotein secreted from hy-
pertrophic glands and/or epithelial cells in bronchioles.
The carbohydrate antigens secreted by the bronchiolar
epithelium in DPB appear in the serum as a result of
airwaydamage in the lower respiratory tract, and serum
levels of the antigens are decreased by a reduction in
neutrophils in BAL £uid after erythromycin (EM)
treatment (26). Serum CA19-9, as well as ESR and CRP,
represents the activity of MAC (9).Kurosu etal showed a
case of MAC in which serum CA19-9 level was remark-
ably elevated on admission, following the 7 weeks of
658 RESPIRATORYMEDICINEadministration of antibiotics RFP, INH,EB and SM,CA19-
9 level was decreased (27).Our results showed that ser-
um CA19-9 in patients with MACwas signi¢cantly high-
er than that in patients withTB, but CRP and ESRwere
lower in the MAC patients. These results indicate that
thehigh serumCA19-9 doesnotre£ect simply theresult
of in£ammation. Thus, MAC infection might a¡ect
bronchioles more predominantly compared withTB in-
fection. Moreover, serum albumin and cholinesterase
were signi¢cantly higher in MAC than in TB group and
thepercentage of patientswho drank alcohol inTBgroup
was signi¢cantly higher than inMAC.These indicate that
MAC infection might be more strongly associated with
impaired defense mechanism of airway but not systemic
defensemechanism, comparedwithTB.
With empiric combination regimens that include clari-
thromycin andusually ethambutol and a rifamycin (rifam-
pin or rifabutin), sputum conversion rates for pulmonary
MAC infection in adultpatients able to tolerate themed-
ications are about 90%) (28). However, both rifampin
and rifabutin induce several P-450 cytochromes, includ-
ing CYP3A4 (29), and clarithromycin concentrations de-
crease to one-forth or less in the presence of rifampin
and rifabutin (29^31).Clarithromycin might have an anti-
in£ammatory activity rather than an antibacterial e¡ect
in the three-drug regimen of clarithromycin, rifampin
and ethambutol.
The e¡ect of low^dose long-termmacrolides has be-
come the standard treatment for DPB and SBS in Japan
(32^34).The low-dose long-term administration of clari-
thromycin is e¡ective for intractable chronic sinusitis
(10,11). Although the therapeutic mechanism of macro-
lides is supposed to be anti-in£ammatory rather than
bactericidal (35,36), the exact mechanism of its action
remains unknown. Many CT scans studies of patients
with MAC infection have showed multiple nodular sha-
dows and bronchiectasis similar to those found in DPB
and SBS (18,19,37). Moreover, our study showed that
MAC infection was characterized by in£ammation of
both the upper and lower airways.Thus, these radiologi-
cal ¢ndings and our results indicate that the therapeutic
mechanism of clarithromycin in a regimen including clar-
ithromycin, rifampin and ethambutol for MAC infection
might be anti-in£ammatory rather than bactericidal, as
in DPB and SBS.
In the present study, the percentage of patients who
smoke in the TB group was signi¢cantly higher than in
the MAC group. Buskin et al showed that smoking had
2.6 times the riskof nonsmokers for pulmonary tubercu-
losis (38). But no evidence has presentedwhether smok-
ing is a risk factor for MAC infection. These indicated
that smoking might be a risk factor forTB, but not for
MAC.
In summary, we found that MAC infection a¡ected
more intensively bronchioles and more frequently asso-
ciated with chronic sinusitis compared with TB. This isthe ¢rst report suggesting that MAC infection may be
strongly associatedwith impaired defensemechanism of
upper and lower airways.We didnot study themicrobio-
logic evaluation of sinusitis. Further studies are needed
to draw the conclusion.
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